{"filing":{"accession_number":"0001213900-26-078173","cik":"0001783036","ticker":"NCEL","company_name":"NewcelX Ltd.","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"ea0297934-6k_newcelx.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1783036/000121390026078173/ea0297934-6k_newcelx.htm"},"events":[{"id":18061,"run_id":16214,"accession_number":"0001213900-26-078173","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"NewcelX announced the grant of a Brazilian patent (BR 112018010946-0) for its NCEL-101 cell selection and enrichment technology, protecting the manufacturing process until November 2036. While this is a positive intellectual property milestone that strengthens the company's global IP portfolio and supports future partnering opportunities, it is primarily an operational/strategic development rather than a discrete material event in the traditional 8-K taxonomy. The patent grant itself is not a financial event (debt, equity, M\u0026A), governance event, or existential threat. However, it is material to investors as it enhances the company's competitive position and IP protection in a strategically important market (Brazil, with ~500,000 T1D patients), particularly in the context of the company's recent FDA Type B Pre-IND meeting success for NCEL-101.","company_name":"NewcelX Ltd.","ticker":"NCEL","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":[{"id":16763,"accession_number":"0001213900-26-078173","item_number":"EX-99.1","item_title":"ea029793401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NewcelX announced the grant of a Brazilian patent (BR 112018010946-0) for its NCEL-101 cell selection and enrichment technology, protecting the manufacturing process until November 2036. While this is a positive intellectual property milestone that strengthens the company's global IP portfolio and supports future partnering opportunities, it is primarily an operational/strategic development rather than a discrete material event in the traditional 8-K taxonomy. The patent grant itself is not a financial event (debt, equity, M\u0026A), governance event, or existential threat. However, it is material to investors as it enhances the company's competitive position and IP protection in a strategically important market (Brazil, with ~500,000 T1D patients), particularly in the context of the company's recent FDA Type B Pre-IND meeting success for NCEL-101.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:42:39.215901+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16763,"accession_number":"0001213900-26-078173","item_number":"EX-99.1","item_title":"ea029793401ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"NewcelX announced the grant of a Brazilian patent (BR 112018010946-0) for its NCEL-101 cell selection and enrichment technology, protecting the manufacturing process until November 2036. While this is a positive intellectual property milestone that strengthens the company's global IP portfolio and supports future partnering opportunities, it is primarily an operational/strategic development rather than a discrete material event in the traditional 8-K taxonomy. The patent grant itself is not a financial event (debt, equity, M\u0026A), governance event, or existential threat. However, it is material to investors as it enhances the company's competitive position and IP protection in a strategically important market (Brazil, with ~500,000 T1D patients), particularly in the context of the company's recent FDA Type B Pre-IND meeting success for NCEL-101.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:42:39.215901+00:00","company_name":"NewcelX Ltd.","ticker":"NCEL","filing_date":"2026-07-15"}]}